CClinicalTrials.gg
CompletedNCT04437459Updated Jun 18, 2020

The Reproducibility and Clinical Utility of an Abbreviated Fat Tolerance Test

An interventional study of High-fat shake and Pure glucose solution in Dyslipidemias and Metabolic Syndrome, sponsored by Oklahoma State University. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Oklahoma State University · Not applicable, Interventional, and Screening

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Oct 2018, registered Jun 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study aims to evaluate the reliability of a shortened fat tolerance test ("abbreviated fat tolerance test", or "AFTT") for measuring post-meal lipids in human blood. The reliability of the triglyceride results in this test are compared to the reliability of the glucose results from an oral glucose tolerance test (OGTT), a widely-used and clinically accepted metabolic test.

02

Conditions studied

  • Dyslipidemias
  • Metabolic Syndrome
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's enrollment of 22 is below the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

Oklahoma State University is the lead sponsor of 38 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Free of chronic disease
  • Normal (healthy) fasting glucose and triglycerides

Exclusion criteria

Exclusion Criteria:

  • Presence of pace-maker
  • Pregnant
  • Using tobacco products
  • Using medications or dietary supplements that could modify primary outcomes
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Abbreviated Fat Tolerance Test

    Other: High-fat shake

  • Active comparator
    Oral Glucose Tolerance Test

    Other: Pure glucose solution

Interventions

  • OtherHigh-fat shake

    Participant consumes a high-fat test shake. Blood is drawn before and 4 hours after this shake to measure triglycerides.

  • OtherPure glucose solution

    Participant consumes 75 grams of pure glucose. Blood is drawn before and 2 hours after this drink to measure glucose.

06

What researchers measure

Primary outcomes

  1. Reliability of the Change in Triglycerides after a High-Fat Meal

    Participants complete two fat tolerance tests. In each test, triglycerides are measured in blood immediately before and 4 hours after consumption of a high-fat meal. The reliability/agreement in measuring the triglyceride change between the 2 tests is being determined.

    Time frame: The two fat tolerance tests are separated by 1 week.

  2. Reliability of the Change in Glucose after Ingestion of a Glucose Solution

    Participants complete two glucose tolerance tests. In each test, glucose is measured in blood immediately before and 2 hours after consumption of a pure glucose solution. The reliability/agreement in measuring the glucose change between the 2 tests is being determined.

    Time frame: The two glucose tolerance tests are separated by 1 week.

07

Study locations

1 site
  • Oklahoma State University
    Stillwater, Oklahoma 74078-6104, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04437459
Lead sponsor
Oklahoma State University
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Oct 8, 2018
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Last update
Jun 18, 2020

Study contacts

Sam R Emerson, PhD
principal investigator · Oklahoma State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion